Quote:
Originally Posted by Harry Z
If one believes Biogen's stats stating that the reduction of risk in disease progression is reduced by 68%, then what about the remaining 32% for patients??!! I hardly doubt that 32% qualifies as "extremely uncommon"!
It's comments like this that really irk me about Tysabri or any other medication that big pharma markets.
Harry
|
It's not the risk in disease progression that is reduced by 68%, Harry, it is the number of relapses that is reduced by 68%.
They really don't expect to see disease "activity" in the way of lesions popping up or getting bigger while people are on Tysabri. Some % of people are ALSO seeing a reduction in disability accumulation too, but having very little lesion activity is what they are measuring to determine "disease progression".
Cherie
__________________
I am not a Neurologist, Physician, Nurse, or Hairdresser ... but I have learned that it is not such a great idea to give oneself a haircut after three margaritas
.